00:00 / 58:38
#1 Inside Marc’s first days at Abivax: what he discovered changed everything
#1
Inside Marc’s first days at Abivax: what he discovered changed everything
#2
The first bold decision that set the entire strategy in motion
05:28
#3
The real reason Abivax didn’t start with Crohn’s
08:39
#4
Why building the phase 3 team in the U.S. became non-negotiable
12:49
#5
The turning point that shaped Abivax’s long-term vision
16:34
#6
How phase 2 learnings quietly engineered a breakthrough phase 3
21:22
#7
The hidden logic behind choosing the most ambitious path for phase 3
26:39
#8
Why Marc’s leadership became the decisive advantage in a high-risk race
29:09
#9
The readout moment: what really happened when the results dropped
36:02
#10
The market reaction no one predicted (not even Marc)
44:49
#11
How big pharma now sees Abivax after its stunning results
50:10
#12
The early clues that convinced Marc this drug could be truly different
53:33
#47 - 600% in 3 Days: the execution playbook behind Abivax’s breakthrough in IBD
“Within three days, we went from almost bankrupt… to one of the stars of the Nasdaq.”
In this conversation, I take you behind the scenes of a biotech journey that sounds almost unbelievable.
Marc de Garidel, CEO of Abivax, tells me how he rebuilt this French biotech from scratch, designed a strategy powerful enough to attract top US investors and executed one of the largest phase 3 programs in ulcerative colitis: a molecule from French public research (CNRS, Institut Curie and the University of Montpellier) which may have a major impact on patients.
This episode is a masterclass in leadership, execution, courage, and long-term thinking.
Here’s what you’ll hear about in this episode:
◾️ How Marc stepped into a company with almost no long-term plan… and why that turned out to be a surprising advantage.
◾️ The four pillars of a new strategy — and how one of them quietly set the stage for the breakthrough to come.
◾️ What it really takes to run a global phase 3 across dozens of countries — and why Abivax had to reinvent itself to pull it off.
◾️ A mechanism of action unlike anything else in IBD — and why this difference matters more than most people think.
◾️ The hidden lessons from a noisy phase 2 that helped transform the phase 3 into something no one saw coming.
◾️ A leadership philosophy built on transparency and speed, born from a single principle: in biotech, every day counts.
◾️ The unexpected market reaction that changed the fate of the company overnight — with numbers that almost don’t seem real.
If you want to hear a real behind-the-scenes story, hit play.
This episode is an exceptional inside look at what it truly takes to turn science into impact, stand your ground under pressure, and lead a biotech from survival… to breakthrough.
—
Find Marc de Garidel:
LinkedIn: https://www.linkedin.com/in/marc-de-garidel-097982/
—
Resources mentioned in the episode:
Abivax https://www.abivax.com/
Pharma Minds episodes mentioned:
His first interview in Pharma Minds in 2023: “CEO Marc De Garidel On Building Something Truly Impactful: Embrace Risks!” https://www.youtube.com/watch?v=mA3-OSltbwQ (in English)
—
🎧 New here? To get a quick overview of the episodes, download “25 Tips for Purposeful Leadership”, a guide inspired by the best advice shared by my guests.
🤝 Want to connect or talk about your current challenges? Let’s connect on LinkedIn.
📩 Curious to dive deeper into the major shifts in the healthcare ecosystem? Subscribe to the Pharma Minds newsletter.
Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.
Powered by Ausha 🚀